Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research

January 8, 2014

LONDON, Jan. 8, 2014 /PRNewswire/ — Edison’s comprehensive report on Cardio3 BioSciences, Healing failing hearts, analyses its C-Cure heart regenerative product, which uses a mix of powerful cell-signalling molecules to programme autologous stem cells to develop into heart muscle. This makes C-Cure a potentially powerful novel treatment for patients with weakened, scarred hearts, usually due to previous heart attacks. C-Cure showed positive efficacy endpoints in Phase II and median heart output increased by 25% relative to baseline. The CHART-1 Phase III in chronic ischaemic heart failure is underway using C-Cath(ez) delivery to improve cell retention 3.6 fold. Data are expected in late 2015.

Based on clinical probabilities of EU 40% and US 25%, our healthcare team identifies the base case indicative value as EUR77 per share. Scenario risk variants range from EUR42 to EUR225 per share.

For the full report see: www.edisoninvestmentresearch.com/research/company/cardio3-biosciences

Keywords: Cardio3 BioSciences, C-Cure, autologous stem cell therapy, ischaemic heart disease, bioscience, healthcare, Edison Investment Research.

All reports published by Edison are available to download free of charge from its website.

Overview of company: Cardio3 is developing a directed autologous stem cell therapy for chronic ischaemic heart disease. Cells are isolated from bone marrow and cultures for six to eight weeks. The product is in Phase III in the EU and on Phase III hold in the US while the FDA considers a delivery system.

About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact:

    Dr John Savin MBA          Edison Investment Research +44 (0)20 3077

    Robin Davison              Edison Investment Research +44 (0)20 3077


Contact details: Learn more at www.edisongroup.com and connect with Edison on

    Linkedin www.linkedin.com/company/edison-investment-research

    Twitter  www.twitter.com/Edison_Inv_Res

    YouTube  www.youtube.com/edisonitv

    Frankfurt +49 (0)69 78 8076 960 London +44 (0)20 3077 5700 New York +1 646 653 7026    Sydney +61 (0)2 9258 1162 Wellington +64 (0)4 8948 555

    Schumannstrasse 34b             280 High Holborn           245 Park Avenue, 39th Floor Level 25, Aurora Place    Level 15, 171 Featherston St

    60325 Frankfurt                 London, WC1V 7EE           10167, New York             88 Phillip Street, Sydney Wellington 6011

    Germany                         United Kingdom             US                          NSW 2000, Australia       New Zealand

SOURCE Edison Investment Research

Source: PR Newswire

comments powered by Disqus